Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Capital Expenditures (2019 - 2025)

Historic Capital Expenditures for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $5.0 million.

  • Beam Therapeutics' Capital Expenditures rose 21775.52% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.2 million, marking a year-over-year increase of 4826.97%. This contributed to the annual value of $8.9 million for FY2024, which is 7347.92% down from last year.
  • Beam Therapeutics' Capital Expenditures amounted to $5.0 million in Q3 2025, which was up 21775.52% from $3.1 million recorded in Q2 2025.
  • Beam Therapeutics' 5-year Capital Expenditures high stood at $16.2 million for Q2 2021, and its period low was $1.6 million during Q3 2024.
  • Moreover, its 5-year median value for Capital Expenditures was $7.9 million (2023), whereas its average is $7.9 million.
  • As far as peak fluctuations go, Beam Therapeutics' Capital Expenditures surged by 58373.47% in 2021, and later tumbled by 8297.74% in 2024.
  • Over the past 5 years, Beam Therapeutics' Capital Expenditures (Quarter) stood at $13.4 million in 2021, then crashed by 38.21% to $8.3 million in 2022, then tumbled by 56.55% to $3.6 million in 2023, then fell by 17.25% to $3.0 million in 2024, then skyrocketed by 68.72% to $5.0 million in 2025.
  • Its Capital Expenditures stands at $5.0 million for Q3 2025, versus $3.1 million for Q2 2025 and $3.1 million for Q1 2025.